Cogstate Expands Executive Team, Appointing Ken Billard as Chief Commercial Officer
November 19, 2019
New Haven, CT – November 19, 2019: The neuroscience technology company, Cogstate Ltd (ASX.CGS), announced today that Ken Billard has joined the company in the role of Chief Commercial Officer. Ken brings proven expertise in sales leadership and strategic partnering to Cogstate, where he will oversee the global sales organization to develop and execute strategies […]
Cogstate to Present at the NORD Rare Diseases and Orphan Products Breakthrough Summit
October 11, 2018
Presentation to Outline Innovative Methodology for Developing Indication-Specific Outcome Measures in Rare Disease Clinical Trials New Haven, CT – October 11, 2018: The cognitive science company, Cogstate Ltd (ASX.CGS) today announced a presentation entitled, “Methodology for Development of Indication-Specific Outcome Measures in Rare Disease Trials: An Innovative Research Approach” will be delivered at the National […]
Cogstate announces European approval for Healthcare offering
June 4, 2018
BOSTON – June 4, 2018: The cognitive science company, Cogstate, today announced that its Healthcare Division has received CE Mark approval for its Cognigram™ digital cognitive assessment system. “Cogstate Healthcare is excited about this significant regulatory milestone and we look forward to joining the fight against brain health challenges in European markets,” said Frank Cheng, […]
Cogstate Scientists Contribute to New Research Framework to Redefine Alzheimer’s Disease
April 17, 2018
A new research framework for understanding Alzheimer’s disease has been developed and released by the Alzheimer’s Association (AA) and the National Institute on Aging (NIA). This framework proposes an important shift in the definition of Alzheimer’s disease from being founded on the presence and nature of symptoms to one based on the identification and characterization of pathologic changes in the […]
Cogstate Establishes Rare Disease and Pediatric Center of Excellence
April 5, 2018
Dr. Pam Ventola appointed to lead implementation as Senior Science Director, Rare Disease and Pediatric Center of Excellence New Haven, CT – April 5, 2018: The cognitive science company, Cogstate Ltd (ASX.CGS) today announced the establishment of a Rare Disease and Pediatric Center of Excellence to lead all activities related to the selection and administration […]
Eric Siemers, M.D., Named Distinguished Medical Adviser at Cogstate
February 27, 2018
Siemers will provide expert advice for Cogstate in neurodegeneration research New Haven, CT – February 27, 2018: The cognitive science company, Cogstate Ltd (ASX.CGS) today announced the appointment of Eric Siemers, M.D., as Distinguished Medical Adviser. Dr. Siemers will provide expert advice for Cogstate’s pharmaceutical customers with regard to the design of clinical trials of […]
International publications validate Cogstate technology’s clinical value in detecting Postoperative Cognitive Dysfunction (POCD)
February 12, 2018
BOSTON – February 13, 2017: From the Interdisciplinary Conference on Orthopedic Value Based Care sponsored by the American College of Perioperative Medicine, Cogstate announced that the Cogstate Brief Battery™ has now been shown to be useful for guiding decision making about cognitive outcomes in older adults awaiting or undergoing surgery. Cogstate Brief Battery is the proprietary […]
Cogstate Strengthens Global Clinical Science Expertise with the Appointment of Senior Vice President, Dr. Chris Edgar
February 9, 2018
New Haven, CT – February 9, 2018: The cognitive science company, Cogstate Ltd (ASX.CGS) today announced the addition of Dr. Chris Edgar, Senior Vice President, Clinical Science to its global scientific leadership team. Dr. Edgar joins the Cogstate team in Europe as an experienced leader in cognitive assessment and clinical endpoint strategy. He will provide […]
Global Alzheimer’s Platform Foundation Selects Cogstate for Industry-First Rater Certification Program
January 24, 2018
Cogstate to Support Rater Training and Certification Program to Enable Accelerated Study Start-up in Alzheimer’s Disease Clinical Trials New Haven, CT – January 24, 2018: The cognitive science company, Cogstate Ltd (ASX.CGS) today announced it has been chosen by the Global Alzheimer’s Platform (GAP) Foundation to support GAP’s rater certification program (RCP) that will significantly […]
New Study Of HIV−Associated Neurocognitive Disorders (HAND) Uses An Innovative Approach To Functional Assessments For Activities Of Daily Living And Correlates To Cogstate Test Performance
November 23, 2017
Navigating the Internet to get daily shopping and banking tasks done has become a necessary skill for just about all of us. Searching for products, comparing pricing, entering credit card and shipping information across multiple websites can sometimes be challenging even for experienced users. But for those persons who also struggle with cognitive dysfunction from […]
New Study Shows Prolonged Site Exposure Among World Trade Center First Responders Is Associated with Cognitive Dysfunction
November 17, 2017
More than sixteen years after the horrific terrorist attacks at the World Trade Center (WTC) in New York City on September 11, 2001, there is still a large segment of the first responders that suffers from cognitive dysfunction as a result of their rescue and recovery efforts. Two leading explanations include the exposure to contaminated […]
Cogstate Announces First U.S. Deployment of the Cognigram™ System at the University of Notre Dame
October 11, 2017
BOSTON – October 11, 2017: The cognitive science company, Cogstate today announced the commercial deployment of its Cognigram™ digital cognitive assessment system at the University of Notre Dame. This placement represents the first Cognigram system commercial implementation in the United States, following the recent FDA notification that the Company can begin marketing the system in […]
Study Evaluates Computer-Based Cognitive Tests to Detect Impairment in Cirrhosis Patients with Hepatic Encephalopathy (HE)
October 11, 2017
Hepatic encephalopathy (HE) is one of the most challenging consequences of cirrhosis, a type of chronic liver disease, as it causes significant cognitive dysfunction in patients. Diagnosing HE has traditionally been done through a psychometric testing battery involving paper and pencil tests designed to assess motor speed, visual perception, visual-spatial orientation, concentration, attention and memory. […]
Cogstate receives positive FDA notification regarding medical device regulatory submission
July 27, 2017
Company to launch COGNIGRAMTM digital cognitive testing tool in U.S. healthcare market Boston, MA – July 27, 2017: The cognitive science company, Cogstate today announced that its healthcare division has received notification from the U.S. Food and Drug Administration (FDA) that the Company’s 510(k) submission (K171658) for the COGNIGRAMTM cognitive assessment system has been reviewed […]
Pilot Study Demonstrates Working Memory Training May Be Effective For Children With Neurofibromatosis
June 27, 2017
While neurofibromatosis often appears in children as visible spots, freckles or tiny bumps, the genetic disorder can also cause learning disabilities, including problems with attention, working memory, inhibition and planning. Up to 40% of children with neurofibromatosis type 1 (NF1) are diagnosed with Attention Deficit/Hyperactivity Disorder (ADHD). These symptoms can often cause issues at home […]
1 2
